NePtune: A Phase 2 Study of Neoadjuvant PARP Inhibition followed by Radical Prostatectomy in Patients with Unfavorable Intermediate-Risk or High-Risk Prostate Cancer with BRCA1/2 Gene Alterations

Status: Open to Accrual

Learn More: 

• https://clinicaltrials.gov/study/NCT05498272

Study Contact: studies@hoosiercancer.org; (317) 921-2050.

Abstracts/Posters/Presentations:

• RR McKay, L Liu, M Pu, A Araneta, L Wang, N Castano, J Gomez, A Ajmera, H Ye, R Pili, K Runcie, D Joseph McHugh, K Offit, C Judith Paller, NB Haas, J Javier-Desloges, CJ Kane, TM Seibert, A Bagrodia. A phase 2 study of neoadjuvant PARP inhibition followed by radical prostatectomy (RP) in patients with unfavorable intermediate-risk or high-risk prostate cancer with BRCA1/2 gene alterations (NePtune) (HCRN-GU20-436). Poster Presentation, 2024 ASCO. See abstract. 
• RR McKay, L Liu, M Pu, A Araneta, L Wang, N Castano, J Gomez, A Ajmera, H Ye, R Pili, K Runcie, D Joseph McHugh, K Offit, C Judith Paller, NB Haas, J Javier-Desloges, CJ Kane, TM Seibert, A Bagrodia. A phase 2 study of neoadjuvant PARP inhibition followed by radical prostatectomy (RP) in patients with unfavorable intermediate-risk or high-risk prostate cancer with BRCA1/2 gene alterations (NePtune) (HCRN-GU20-436). Trials in Progress, 2024 ASCO GU. See abstract.